Etentamig + Dexamethasone + Lenalidomide + Pomalidomide + Daratumumab
Phase 1Active 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Multiple Myeloma
Conditions
Relapsed/Refractory Multiple Myeloma
Trial Timeline
Oct 20, 2022 → Sep 1, 2033
NCT ID
NCT05259839About Etentamig + Dexamethasone + Lenalidomide + Pomalidomide + Daratumumab
Etentamig + Dexamethasone + Lenalidomide + Pomalidomide + Daratumumab is a phase 1 stage product being developed by AbbVie for Relapsed/Refractory Multiple Myeloma. The current trial status is active. This product is registered under clinical trial identifier NCT05259839. Target conditions include Relapsed/Refractory Multiple Myeloma.
What happened to similar drugs?
0 of 10 similar drugs in Relapsed/Refractory Multiple Myeloma were approved
Approved (0) Terminated (1) Active (9)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3
Hype Score Breakdown
Clinical
6
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05259839 | Phase 1 | Active |
Competing Products
20 competing products in Relapsed/Refractory Multiple Myeloma